Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer shares have declined approximately 7% over the past 30 days, pressured by a surprise CFO departure and mixed clinical trial results.
• The company reaffirmed its full-year 2026 guidance, projecting revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00.
• FDA approval of Ibrance for a new metastatic breast cancer indication strengthens Pfizer’s oncology franchise, while a lung cancer trial miss highlights pipeline risk.
• Analyst consensus remains a “Buy” with a 12-month price target of $29.15, implying over 20% upside from current levels.
• A forward P/E of 8.5 and a dividend yield above 7% continue to attract value-oriented investors, though patent cliff headwinds persist.

Current Market Snapshot

Pfizer Inc. (PFE) has experienced a modest pullback in recent weeks, with the stock trading near $24.25 as of late June 2026. The shares have slipped roughly 7% over the past month, underperforming the broader healthcare sector. The decline was largely triggered by the unexpected announcement that CFO Dave Denton will step down in August, alongside disappointing topline results from a late-stage lung cancer trial. Despite these headwinds, the stock remains within its 52-week range of $23.11 to $28.75, and the company’s robust dividend yield continues to provide a floor for income-focused investors. Trading volumes have been elevated during the recent sell-off, suggesting active repositioning by institutional investors.

Pfizer Inc. (PFE) Business Overview and Competitive Position

Pfizer is one of the world’s largest research-based biopharmaceutical companies, with a diversified portfolio spanning oncology, vaccines, internal medicine, immunology, and rare diseases. The company’s top-selling products include the breast cancer drug Ibrance, the cardiovascular therapy Vyndaqel, the anticoagulant Eliquis, and the pneumococcal vaccine Prevnar. Following its acquisition of Seagen, Pfizer has significantly expanded its oncology pipeline, particularly in antibody-drug conjugates (ADCs). The company also holds a strong position in biosimilars and sterile injectables. With approximately $63 billion in trailing revenue and a presence in more than 100 countries, Pfizer remains a dominant force in global healthcare, though it faces a well-known patent cliff that will erode exclusivity on several key products through 2028.

Recent Developments Driving PFE

Several high-impact events have shaped Pfizer’s stock performance over the past 30 days. On June 18, the company disclosed that CFO Dave Denton will leave on August 15 for a role in the consumer goods industry. Cecile Guegan, a two-decade Pfizer veteran, will serve as interim CFO while a permanent successor is sought. The news sent shares down nearly 3% in a single session, though management quickly reaffirmed all components of its 2026 financial guidance.

On the pipeline front, Pfizer announced that the Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-small cell lung cancer missed its primary overall survival endpoint in the broader population, though encouraging signals were observed in second-line patients. Conversely, the FDA approved an expanded label for Ibrance, making it the first CDK4/6 inhibitor indicated for HR+, HER2+ metastatic breast cancer maintenance therapy. The PATINA trial showed a 24% reduction in the risk of disease progression.

Additionally, Pfizer was dismissed from a multi-state generic drug price-fixing lawsuit, removing a legal overhang. RBC Capital upgraded the stock to Sector Perform from Underperform, citing a more balanced risk-reward profile. The company also declared a $0.43 quarterly dividend, reinforcing its commitment to shareholder returns.

Trending AI Robots

For investors seeking data-driven insights, Tickeron’s Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered bots that trade thousands of tickers across various strategies and timeframes, but only the most relevant and consistently high-performing bots are featured in this section. These bots utilize technical analysis, pattern recognition, and fundamental algorithms to identify potential opportunities. Whether you are looking for short-term swing trades or longer-term trend-following strategies, the Trending AI Robots page provides a transparent view of real-time performance metrics. Explore the page to see which bots are currently leading the market.

2026 Outlook and What Investors Should Watch

Pfizer’s 2026 outlook is anchored by its guidance for $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00, reflecting a year-over-year decline driven by lower COVID-19 product sales and an estimated $1.5 billion headwind from loss of exclusivity on key drugs. The company expects operational revenue growth of approximately 4% when excluding COVID and LOE products, signaling underlying momentum in its core business.

Investors should monitor several catalysts in the second half of 2026. The next earnings report, scheduled for August 4, will be closely watched for updates on the CFO transition and any adjustments to guidance. Key pipeline readouts include further data from the Seagen ADC portfolio, particularly in bladder cancer, and progress on the Metsera-acquired obesity assets, which target a 2028+ launch. The integration of cost realignment programs and the trajectory of adjusted R&D and SI&A expenses will also be critical for margin expansion. On the macro front, potential U.S. drug pricing policy changes and global trade dynamics could impact Pfizer’s international operations. While the stock’s low forward P/E and high dividend yield offer a margin of safety, the pace of pipeline execution and management stability will ultimately determine whether Pfizer can navigate its patent cliff and return to sustainable growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.